Strategic Growth Acquisition of TigaTx and board expansion signal aggressive expansion into pan-isotype cancer antibody platforms, presenting opportunities to cross-sell development and collaboration services, as well as co-development discussions with in-house IgE and IgA capabilities.

Clinical Momentum Lead program in phase I targeting FR alpha for ovarian cancer and the world’s first IgE therapeutic clinic entry position Epsilogen as a potential partner for clinical trial support services, contract manufacturing, and biomarker collaboration.

Financial Backing Strong funding runway with Series B totals and notable backers, indicating a willingness to engage in strategic partnerships, licensing, or milestone-rich collaboration deals with larger pharma and biotech players.

Executive Access New Chief Medical Officer appointment alongside experienced board addition creates executive-level engagement pressure points for potential advisory roles, joint development discussions, and high-level strategic collaborations.

Global Ops Readiness Global leadership position and diversified tech stack plus international HQ presence suggest capability for scaled partnerships, remote clinical operations support, and multi-regional manufacturing or data management collaborations.